Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder


I'm Interested

Trial ID: NCT03187769


This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness

Official Title

A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, or Bipolar I Disorder Who Are Early in Their Illness

Stanford Investigator(s)

Jacob S. Ballon
Jacob S. Ballon

Associate Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology)


Inclusion Criteria:

   - Has less than 24 weeks previous treatment with antipsychotics (cumulative; lifetime)

      - Subject treated with aripiprazole can receive an additional 1 year of treatment
      at ≤5 mg/day, and this treatment will not be considered as part of the 24 weeks
      of previous treatment with antipsychotics

   - Has less than 4 years elapse since the initial onset of active-phase of symptoms

   - Has a body mass index (BMI) of <30 kg/m^2

   - Agrees to use an acceptable method of contraception for the duration of the study and
   for 30 days after the last dose of study drug

   - Subject meets the criteria for a primary diagnosis of schizophrenia, schizophreniform
   disorder, or bipolar I disorder

   - For bipolar I disorder, must have been experiencing an episode of acute mania within
   ≤14 days prior to Visit 1

   - Suitable for outpatient treatment

   - Additional criteria may apply

Exclusion Criteria:

   - Poses a current suicide risk

   - Has a history of poor or inadequate response to treatment with olanzapine

   - Has previously been treated with long-acting injectable antipsychotic medication
   within the 2 months prior to screening, or has > 6 months cumulative life use, or has
   received treatment with electroconvulsive therapy in their lifetime

   - Has initiated treatment with mood stabilizers (eg lithium, valproate, etc) >2 months
   prior to Visit 1

   - Has a positive drug screen for opioids, phencyclidine (PCP),
   amphetamine/methamphetamine, or cocaine

   - Has taken opioid agonists (eg, codeine, oxycodone, tramadol, morphine) within the 14
   days prior to Visit 1, or has taken opioid antagonists, including naltrexone and
   naloxone, within 60 days prior to Visit 1

   - Taking any weight loss agents or hypoglycemic agents

   - Has a clinically significant or unstable medical illness, condition, or disorder that
   would be anticipated to potentially compromise subject safety or adversely affect the
   evaluation of efficacy

   - Has joined a weight management program or had significant changes in diet or exercise
   regimen within the past 6 weeks

   - Has started a smoking cessation program within the past 6 months

   - Has a history of diabetes

   - Currently pregnant or breastfeeding or is planning to become pregnant during the study
   or within 30 days of the last study drug administration

   - Additional criteria may apply


drug: ALKS 3831

drug: Olanzapine


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305